A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC

This study is testing M701 — a bispecific antibody that targets both cancer cells and immune cells to help the immune system attack tumors — for patients with non-small cell lung cancer (NSCLC) that has caused a malignant pleural effusion (a build-up of cancer-containing fluid around the lung). This fluid is a sign that the cancer has spread to the lining of the lung, which is very difficult to treat. **You may be eligible if:** - You are 18 years or older - You have been confirmed to have NSCLC that has progressed after at least one prior systemic treatment - You have a moderate-to-large malignant pleural effusion confirmed by imaging and cytology - Your general health is adequate for treatment **You may NOT be eligible if:** - Your cancer has not been previously treated with systemic therapy - You have active autoimmune disease or are on immunosuppressive drugs - You have uncontrolled brain metastases - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.